Loading patent…
AssigneesDIOSynVax Ltd, Cambridge Enterprise Limited
InventorsJonathan Luke HEENEY, Sneha VISHWANATH, Matteo FERRARI, George CARNELL
Estimating the term…
Designed coronavirus polypeptide sequences are described, and their use as vaccines against viruses of the coronavirus family. The designed sequences include designed coronavirus spike(S) proteins and fragments thereof, including CoV_S_T2_35 (SEQ ID 5 NO: 1), CoV_S_T2_36 (SEQ ID NO:2), and Omicron_vaccine (SEQ ID NO:3). Variants of CoV_S_T2_35 (deom) are also described, including CoV_S_T3_1 (SEQ ID NO:31) and CoV_S_T3_2 (SEQ ID NO:32), and fragments thereof. Nucleic acid molecules encoding the polypeptides, vectors, fusion proteins, pharmaceutical compositions, cells, and their use as vaccines against viruses of the coronavirus family are also described.
An isolated polypeptide which comprises an amino acid sequence of SEQ ID NO:1 (CoV_S_T2_35), or an amino acid sequence which has at least 97%, 98%, or 99% amino acid identity over its entire length with the amino acid sequence of SEQ ID NO:1.
A polypeptide according to any preceding claim, which comprises the amino acid residues of SEQ ID NO:1, at positions corresponding to the amino acid residue positions of SEQ ID NO:
A polypeptide according to any preceding claim, which comprises the following amino acid residues at positions corresponding to residues 984, and 985, of SEQ ID NO:8:
A polypeptide according to any preceding claim, which comprises the following amino acid residues at positions corresponding to residues 680, 681, 683, 984, and 985, of SEQ ID NO:8:
A polypeptide according to any preceding claim, which comprises the amino acid residues of SEQ ID NO:1, at positions corresponding to the amino acid residue positions of SEQ ID NO:
A polypeptide according to any preceding claim, which does not include residues KFDEDDSEPVLKGVKLHYT at positions corresponding to amino acid residue positions 1253-1271 of SEQ ID NO:8.
A polypeptide according to any preceding claim which comprises CoV_S_T2_35(deom) amino acid sequence (SEQ ID NO:1).
An isolated polypeptide which comprises a coronavirus S protein with at least one, or all of the amino acid residues, at positions corresponding to the amino acid residue positions of SEQ ID NO:8, as shown in Table 3 below:
An isolated polypeptide, which comprises the amino acid sequence of SEQ ID NO:2 5 (CoV_S_T2_36), or an amino acid which has at least 97%, 98%, or 99% amino acid identity over its entire length with the amino acid sequence of SEQ ID NO:2.
An isolated polypeptide which comprises a coronavirus S protein with at least one, or all of the amino acid residues, at positions corresponding to the amino acid residue positions of SEQ ID NO:9, as shown in Table 6 below:
An isolated polypeptide, which comprises an amino acid sequence of SEQ ID NO:3 (Omicron_vaccine), or an amino acid which has at least 99% amino acid identity over its entire length with the amino acid sequence of SEQ ID NO:3.
An isolated polypeptide which comprises an amino acid sequence of SEQ ID NO:30 (CoV_S_T2_35 Scaffold Sequence), wherein X at amino acid residue positions 337, 344, 366, 371, 373, 374, 403, 406, 443, 444, 450, 458, 484, 488, 491, and 494, is any amino acid residue.
An isolated polypeptide which comprises an amino acid sequence of SEQ ID NO:33 (RBD portion of CoV_S_T2_35 Scaffold Sequence (SEQ ID NO:30)), wherein X at amino acid residue positions corresponding to amino acid residue positions 337, 344, 366, 371, 373, 374, 403, 406, 443, 444, 450, 458, 484, 488, 491, and 494, of SEQ ID NO:30, is any amino acid residue.
A vector according to any of claims to 60 to 63, which further comprises a promoter operably linked to the nucleic acid.
Dependencies are inferred from the claim text.